Distinct pathways in the pathogenesis of sebaceous carcinomas implicated by differentially expressed microRNAs.

IMPORTANCE The molecular-genetic alterations contributing to the pathogenesis of sebaceous carcinoma and sebaceous adenoma remain poorly understood. Given that sebaceous carcinoma is associated with substantial morbidity and mortality, there is a critical need to delineate the pathways driving sebaceous carcinoma and candidate molecules for targeted therapy. OBJECTIVE To describe differentially expressed microRNAs (miRNAs) in a series of periocular sebaceous carcinomas compared with sebaceous adenomas in order to identify pathways driving the pathogenesis of sebaceous carcinoma. DESIGN, SETTING, AND PARTICIPANTS Thirty sebaceous carcinomas and 23 sebaceous adenomas (including 11 that were confirmed to be related to Muir-Torre syndrome and 6 that were confirmed to be sporadic) were obtained from archives (from 48 patients) of 2 institutions (University of Texas MD Anderson Cancer Center, Houston, and Siriraj Hospital, Mahidol University, Bangkok, Thailand) and profiled. MAIN OUTCOMES AND MEASURES Expression of miRNAs was determined using total RNA from formalin-fixed, paraffin-embedded tissue and real-time reverse transcription-polymerase chain reaction performed in a microfluidics card containing 378 unique miRNAs. Fold change was determined using the ΔΔCt method (reference probe, RNU48). Median centering was used to normalize the data. Two-sample t tests were used to identify differentially expressed miRNAs. The false discovery rate was assessed by β-uniform mixture analysis of P values from the t statistics. Significance was defined by this estimated false discovery rate. RESULTS Serial testing and validation confirmed overexpression of 2 miRNAs previously reported to be oncogenic, miR-486-5p (4.4-fold; P = 2.4 × 10-8) and miR-184 (3.5-fold; P = 1.7 × 10-6), in sebaceous carcinoma compared with sebaceous adenoma and downregulation of 2 miRNAs previously reported to have tumor-suppressive properties, miR-211 (-5.8-fold; P = 2.3 × 10-9) and miR-518d (-4.5-fold; 6.7 × 10-5), in sebaceous carcinoma compared with sebaceous adenoma. CONCLUSIONS AND RELEVANCE Sebaceous carcinoma exhibits an miRNA expression profile distinct from that of sebaceous adenoma, implicating dysregulation of NF-κB and PTEN (targets of miR-486-5p) and TGF-β signaling (target of miR-211) in the pathogenesis of sebaceous carcinoma. The identification of miRNAs whose expression is altered in sebaceous carcinoma compared with sebaceous adenoma provides a novel entry point for a more comprehensive understanding of the molecular-genetic alterations pivotal to the development of sebaceous carcinoma.

[1]  J. Qu,et al.  Regulation of pigmentation by microRNAs: MITF‐dependent microRNA‐211 targets TGF‐β receptor 2 , 2015, Pigment cell & melanoma research.

[2]  P. Fisher,et al.  Suppression of miR-184 in malignant gliomas upregulates SND1 and promotes tumor aggressiveness. , 2015, Neuro-oncology.

[3]  B. Göttgens,et al.  MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome. , 2015, Blood.

[4]  J. Hou,et al.  MicroRNA‐486‐5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1 , 2015, The FEBS journal.

[5]  Xianghong Zhang,et al.  Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer , 2014, Molecular Cancer.

[6]  Xiaohong Wang,et al.  MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells , 2014, Tumor Biology.

[7]  Huiling Yang,et al.  Candidate tumour suppressor CCDC19 regulates miR-184 direct targeting of C-Myc thereby suppressing cell growth in non-small cell lung cancers , 2014, Journal of cellular and molecular medicine.

[8]  Jamie L. Marshall,et al.  MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms. , 2014, The Journal of clinical investigation.

[9]  A. Facchiano,et al.  Comprehensive analysis of PTEN status in Sezary syndrome. , 2013, Blood.

[10]  Shu-Chun Lin,et al.  miR-211 promotes the progression of head and neck carcinomas by targeting TGFβRII. , 2013, Cancer letters.

[11]  C. Croce,et al.  Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer , 2013, Proceedings of the National Academy of Sciences.

[12]  Libing Song,et al.  miR-486 sustains NF-κB activity by disrupting multiple NF-κB-negative feedback loops , 2012, Cell Research.

[13]  K. Oikawa,et al.  TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcoma. , 2012, Biochemical and biophysical research communications.

[14]  B. Esmaeli,et al.  American Joint Committee on Cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival. , 2012, Ophthalmology.

[15]  T. Brenn,et al.  Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors , 2012, British Journal of Cancer.

[16]  L. Kunkel,et al.  Regulation of DMD pathology by an ankyrin-encoded miRNA , 2011, Skeletal Muscle.

[17]  Elke Hacker,et al.  Melanoma cell invasiveness is regulated by miR‐211 suppression of the BRN2 transcription factor , 2011, Pigment cell & melanoma research.

[18]  G. Russo,et al.  MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome , 2011, Cell Death and Disease.

[19]  N. Palanisamy,et al.  Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Antiapoptotic Factor in Gastric Cancer , 2011, Clinical Cancer Research.

[20]  B. Esmaeli,et al.  Positive sentinel node in sebaceous carcinoma of the eyelid. , 2011, Ophthalmic plastic and reconstructive surgery.

[21]  R. Govindan,et al.  Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  Jun Li,et al.  Biomarkers , Genomics , Proteomics , and Gene Regulation miR-182 as a Prognostic Marker for Glioma Progression and Patient Survival , 2010 .

[23]  Kai Stühler,et al.  Identification and Functional Characterization of microRNAs Involved in the Malignant Progression of Gliomas , 2010, Brain pathology.

[24]  E. Olson,et al.  Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486 , 2010, Proceedings of the National Academy of Sciences.

[25]  M. O'sullivan,et al.  MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2 , 2010, Molecular Cancer.

[26]  F. Nielsen,et al.  MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. , 2009, The Journal of investigative dermatology.

[27]  D. Elder,et al.  MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. , 2009, International journal of clinical and experimental pathology.

[28]  D. Bartel MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[29]  William Ignace Wei,et al.  Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue , 2008, Clinical Cancer Research.

[30]  B. Esmaeli,et al.  Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid , 2008, International journal of dermatology.

[31]  Li Liao-qin Sebaceous carcinoma of the eyelid:a clinicopathological study , 2007 .

[32]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[33]  M. Beal,et al.  Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice , 2006, Journal of the Neurological Sciences.

[34]  C. Croce,et al.  MicroRNA expression and function in cancer. , 2006, Trends in molecular medicine.

[35]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[36]  C. Croce,et al.  MicroRNAs and chromosomal abnormalities in cancer cells , 2006, Oncogene.

[37]  C. Croce,et al.  Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. , 2006, Seminars in oncology.

[38]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  George A. Calin,et al.  Mammalian microRNAs: a small world for fine-tuning gene expression , 2006, Mammalian Genome.

[40]  C. Shields,et al.  Sebaceous carcinoma of the ocular region: a review. , 2005, Survey of ophthalmology.

[41]  C. Shields,et al.  Sebaceous carcinoma of the eyelids: personal experience with 60 cases. , 2004, Ophthalmology.

[42]  C. Croce,et al.  MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[45]  Stan Pounds,et al.  Estimating the Occurrence of False Positives and False Negatives in Microarray Studies by Approximating and Partitioning the Empirical Distribution of P-values , 2003, Bioinform..

[46]  B. Nelson,et al.  Sebaceous carcinoma. , 1995, Journal of the American Academy of Dermatology.

[47]  L. G. Kass,et al.  Sebaceous carcinoma of the ocular adnexa. , 1989, Survey of ophthalmology.

[48]  I. McLean,et al.  Sebaceous carcinomas of the ocular adnexa: A clinicopathologic study of 104 cases, with five-year follow-up data. , 1982, Human pathology.